New guidelines recommend starting cholesterol drugs in 30s for high-risk patients

A coalition of major medical organizations released updated guidance on Friday that fundamentally shifts when doctors should consider prescribing cholesterol-lowering drugs. Instead of waiting until middle age, cardiologists and their peers now recommend that adults as young as 30 with certain risk factors begin statin therapy—a change that could extend treatment to millions of Americans who would not have qualified under previous standards.

The new guidelines, developed by the American College of Cardiology, the American Heart Association, and nine other medical groups, emphasize a departure from decades of practice. Doctors have traditionally assessed cardiovascular risk over a ten-year window, a timeframe that typically shows low risk for people in their thirties. The updated approach instead projects risk across thirty years, recognizing that cholesterol damage accumulates over a lifetime. Adults starting in their thirties with LDL cholesterol of 160 milligrams per deciliter or higher, a strong family history of premature heart disease, or a high projected thirty-year cardiovascular risk should now consider statin therapy alongside diet and exercise changes. The 123-page guideline makes clear that waiting carries a cost: reducing lifetime exposure to cholesterol and the plaque it builds in arteries translates directly to fewer heart attacks and strokes decades later.

The scope of this shift is substantial. Roughly 65 to 70 million Americans fall between ages 30 and 44. Even if only a fraction of that population meets the new criteria, the number potentially qualifying for statin therapy could reach into the millions. Dr. Jennifer Haythe, co-director of the Women's Heart Center at NewYork-Presbyterian/Columbia University Irving Medical Center, noted that the trial evidence supporting early treatment is robust: longer periods of reduced LDL exposure demonstrably prevent plaque accumulation. For those who begin statins young, the goal is to lower LDL to less than 100 milligrams per deciliter; for highest-risk patients, the target drops to less than 55. The guideline recommends using a newer risk calculator—the American Heart Association's PREVENT online tool—to evaluate both ten-year and thirty-year risk profiles for adults ages 30 to 79.

The medical rationale centers on a simple principle: time matters. Starting treatment early may allow doctors to use lower doses while still achieving protective effects, reducing the risk of side effects like muscle pain or liver damage that can accompany higher statin doses. One cardiologist noted that this approach represents a long-overdue recognition that lifetime cholesterol burden, not just immediate risk, drives whether someone will experience a heart attack, stroke, or sudden cardiac death. The guidelines emphasize, however, that risk calculators start conversations rather than write prescriptions. Final decisions rest with patients after discussion with their doctors, potentially over multiple visits.

The human stakes of delayed treatment became visceral in the story of Gigi Gari Campos, now 37 and an American Heart Association volunteer. Campos grew up knowing she carried familial hypercholesterolemia, an inherited genetic disorder that causes dangerously high cholesterol from birth. Her doctors were reluctant to start her on statins during her childbearing years, citing FDA guidance that statins pose potential risks to pregnancy. They recommended waiting until after she had children. Campos, who had no plans to start a family, pushed back and eventually began treatment. After several months on medication, her cholesterol was dropping but remained elevated.

At 34, on what she describes as an ordinary day—a two-mile walk with her husband—Campos felt chest pressure. She initially wondered if she had slept wrong. The discomfort persisted through the morning, and she drove to urgent care, where tests revealed an unusual heart rhythm. An ambulance transported her to the hospital, where doctors determined she needed a cardiac catheterization to clear blockages. As medical staff prepared her for the procedure, she went into cardiac arrest. She remembers a nurse asking if she felt okay, remembers saying she felt faint, remembers her eyes rolling back before the team shocked her heart back to life. She went into cardiac arrest a second time before the procedure was completed and the blockages cleared.

Since her near-fatal event, Campos has taken statins nightly without side effects, along with two other medications, a healthy diet, and regular exercise. Her total cholesterol has dropped from around 400 milligrams per deciliter at the time of her arrest to less than 100. Her LDL—the "bad" cholesterol—now sits in the 20s. She speaks about the experience with the clarity of someone who understands she survived by inches. "If there was medical consensus, and every single doctor I saw would have said, 'We know you need to start now or as soon as possible,' then it would have been a very different journey for me," she said. Heart disease remains the leading cause of death in the United States, claiming one life every 34 seconds. The updated guidelines represent an attempt to shift that calculus by catching risk earlier, before it becomes a crisis in an ICU bed.